Loading...

G1 Therapeutics

DB:G1H
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
G1H
DB
$682M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
G1H Share Price and Events
7 Day Returns
8.6%
DB:G1H
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-48.3%
DB:G1H
-5.6%
DE Biotechs
-4.5%
DE Market
G1H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
G1 Therapeutics (G1H) 8.6% 28% -8.3% -48.3% - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • G1H underperformed the Biotechs industry which returned -5.6% over the past year.
  • G1H underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

G1H Value

 Is G1 Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for G1 Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €16.67.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for G1 Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are G1 Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:G1H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.56
NasdaqGS:GTHX Share Price ** NasdaqGS (2019-04-25) in USD $18.24
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of G1 Therapeutics.

DB:G1H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:GTHX Share Price ÷ EPS (both in USD)

= 18.24 ÷ -2.56

-7.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • G1 Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • G1 Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does G1 Therapeutics's expected growth come at a high price?
Raw Data
DB:G1H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
-0.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for G1 Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on G1 Therapeutics's assets?
Raw Data
DB:G1H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $9.63
NasdaqGS:GTHX Share Price * NasdaqGS (2019-04-25) in USD $18.24
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:G1H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:GTHX Share Price ÷ Book Value per Share (both in USD)

= 18.24 ÷ 9.63

1.89x

* Primary Listing of G1 Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • G1 Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess G1 Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. G1 Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

G1H Future Performance

 How is G1 Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is G1 Therapeutics expected to grow at an attractive rate?
  • G1 Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • G1 Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Unable to compare G1 Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:G1H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:G1H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts -0.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:G1H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:G1H Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 451 155 45 6
2022-12-31 130 -185 -200 6
2021-12-31 39 -146 -132 5
2020-12-31 0 -139 -148 8
2019-12-31 0 -105 -115 8
DB:G1H Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -74 -85
2018-09-30 -68 -78
2018-06-30 -65 -74
2018-03-31 -59 -68
2017-12-31 -51 -65
2017-09-30 -45 -60
2017-06-30 -37 -52
2017-03-31 -29 -45
2016-12-31 -25 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • G1 Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if G1 Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:G1H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from G1 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G1H Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.97 9.82 0.18 3.00
2022-12-31 -1.98 -1.87 -2.09 2.00
2021-12-31 -3.06 -1.82 -4.08 5.00
2020-12-31 -3.41 -3.16 -3.78 6.00
2019-12-31 -3.01 -2.73 -3.54 7.00
DB:G1H Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.56
2018-09-30 -2.51
2018-06-30 -2.48
2018-03-31 -2.72
2017-12-31 -3.57
2017-09-30 -5.20
2017-06-30 -11.02
2017-03-31 -29.86
2016-12-31 -23.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if G1 Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess G1 Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
G1 Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

G1H Past Performance

  How has G1 Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare G1 Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • G1 Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare G1 Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare G1 Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
G1 Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from G1 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G1H Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -85.29 18.60 70.68
2018-09-30 -78.18 13.80
2018-06-30 -73.86 10.73
2018-03-31 -68.48 9.17
2017-12-31 -64.88 7.09 53.88
2017-09-30 -59.50 6.14
2017-06-30 -51.66 5.19
2017-03-31 -44.55 4.45
2016-12-31 -34.70 5.23 25.16
2015-12-31 0.52 -21.69 3.22
2014-12-31 1.04 -7.18 2.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if G1 Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if G1 Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if G1 Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess G1 Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
G1 Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

G1H Health

 How is G1 Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up G1 Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • G1 Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • G1 Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of G1 Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • G1 Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from G1 Therapeutics Company Filings, last reported 3 months ago.

DB:G1H Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 358.82 0.00 369.29
2018-09-30 379.26 0.00 390.52
2018-06-30 176.52 0.00 188.23
2018-03-31 183.16 0.00 194.39
2017-12-31 93.39 0.00 103.81
2017-09-30 109.13 0.00 118.38
2017-06-30 123.69 0.00 132.68
2017-03-31 30.79 0.00 37.73
2016-12-31 42.59 0.00 47.31
2015-12-31 21.73 0.00 22.94
2014-12-31 3.47 0.00 3.69
  • G1 Therapeutics has no debt.
  • G1 Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • G1 Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • G1 Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 47.2% each year.
X
Financial health checks
We assess G1 Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. G1 Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

G1H Dividends

 What is G1 Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from G1 Therapeutics dividends.
If you bought €2,000 of G1 Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate G1 Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate G1 Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:G1H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:G1H Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as G1 Therapeutics has not reported any payouts.
  • Unable to verify if G1 Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of G1 Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as G1 Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess G1 Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can G1 Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. G1 Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

G1H Management

 What is the CEO of G1 Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Velleca
COMPENSATION $738,217
AGE 54
TENURE AS CEO 4.9 years
CEO Bio

Dr. Mark A. Velleca, M.D., Ph.D., has been Chief Executive Officer of G1 Therapeutics, Inc. since May 20, 2014 and has been its President since May 2014. Dr. Velleca served as Senior Advisor at Gilead Sciences, Inc. from 2010 to April 2012, where he worked to help build its oncology pipeline. He was a Co-founder of CGI Pharmaceuticals, Inc. and served as its Senior Vice President from 1999 to 2010. He served as Executive vice president at The Leukemia & Lymphoma Society (LLS) from April 2012 to April 2014. Dr. Velleca joined LLS in 2012 as chief policy and advocacy officer and was responsible for the strategy and implementation of its legislative and regulatory policy initiatives. He served as Vice President of Research and Preclinical Development of CGI Pharmaceuticals, Inc. Dr. Velleca serves as First Employee at CGI and one of its founding scientists. He has more than 15 years of broad-based experience in both basic biomedical research and clinical medicine. He is expertise in the laboratory diagnosis of autoimmune/inflammatory diseases, hematological disorders and cancer, as well as the treatment of cancer patients via stem cell transplantation. He served as Chief Scientific Officer of CGI Pharmaceuticals, Inc. Since CGI's formation, Dr. Velleca has played a leading role in the design and implementation of its scientific strategy for drug discovery and development. He was Chief Resident at Yale New Haven Hospital. He served as a Member of Scientific Advisory Board at BioRelix, Inc from 2007 to 2012. He has been a Director of G1 Therapeutics, Inc. since May 2014. He served as a Director of BioMarker Strategies, LLC from 2010 to 2012. He served as a Member of Scientific Advisory Board of Intellikine, Inc. from 2007 to 2010. Dr. Velleca was on the faculty of Yale Medical School. An attending Physician at Yale New Haven Hospital until 2002, Dr. Velleca maintained an adjunct appointment at Yale University as a Clinical Assistant Professor of Laboratory Medicine. He has published papers in diverse areas of cell and molecular biology, signal transduction, immunology, neuroscience and transfusion medicine. He is the recipient of a NIH Physician/ Scientist Career Award. He is a Board-Certified Clinical Pathologist. Dr. Velleca earned his B.S. Cum Laude from Yale University and is a graduate of the Medical Scientist Training Program at Washington University. He received an M.D. and a Ph.D. in the Neurosciences from Washington University in St. Louis. After completing clinical training at Yale New Haven Hospital, Dr. Velleca did postdoctoral research in Cell Biology and Immunobiology at Yale Medical School.

CEO Compensation
  • Mark's compensation has been consistent with company performance over the past year.
  • Mark's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the G1 Therapeutics management team in years:

1.5
Average Tenure
54
Average Age
  • The average tenure for the G1 Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Mark Velleca

TITLE
CEO, President & Director
COMPENSATION
$738K
AGE
54
TENURE
4.9 yrs

Buck Phillips

TITLE
CFO, Senior VP of Corporate Development & Secretary
COMPENSATION
$3M
AGE
55
TENURE
1.4 yrs

Terry Murdock

TITLE
Senior Vice President of Development Operations
COMPENSATION
$1M
AGE
58
TENURE
1.7 yrs

Lex Smith

TITLE
Vice President of Technical Operations
TENURE
4 yrs

Jay Strum

TITLE
Chief Scientific Officer
AGE
54
TENURE
10.3 yrs

Jennifer Moses

TITLE
VP of Finance & Administration
AGE
43
TENURE
4.1 yrs

Jeff Macdonald

TITLE
Head of Investor & Public Relations
TENURE
1.3 yrs

Blake Jensen

TITLE
Vice President of Quality & Compliance
TENURE
1.3 yrs

James Hanson

TITLE
General Counsel
TENURE
0.8 yrs

JoAnne Zellner

TITLE
Head of Human Resources
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the G1 Therapeutics board of directors in years:

4.2
Average Tenure
61
Average Age
  • The tenure for the G1 Therapeutics board of directors is about average.
Board of Directors

Seth Rudnick

TITLE
Chairman of the Board of Directors & Member of Advisory Board
COMPENSATION
$258K
AGE
69
TENURE
5.3 yrs

Mark Velleca

TITLE
CEO, President & Director
COMPENSATION
$738K
AGE
54
TENURE
4.9 yrs

Glenn Muir

TITLE
Director
COMPENSATION
$237K
AGE
59
TENURE
3.6 yrs

Cynthia Schwalm

TITLE
Independent Director
AGE
58
TENURE
0.8 yrs

Kwok-Kin Wong

TITLE
Co-Founder & Member of Scientific Advisory Board

George Demetri

TITLE
Scientific & Clinical Advisor
AGE
61

Joseph Bailes

TITLE
Scientific & Clinical Advisor
AGE
61

Geoffrey Shapiro

TITLE
Scientific & Clinical Advisor

Fred Eshelman

TITLE
Director
COMPENSATION
$229K
AGE
69
TENURE
4.2 yrs

Gary Lyman

TITLE
Scientific & Clinical Advisor
AGE
72
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Dec 18 Buy James Hanson Individual 26. Dec 18 26. Dec 18 1,000 €16.00 €15,996
27. Dec 18 Buy Cynthia Schwalm Individual 26. Dec 18 26. Dec 18 1,420 €16.17 €22,961
11. Dec 18 Buy James Hanson Individual 10. Dec 18 10. Dec 18 1,000 €28.60 €28,597
11. Dec 18 Buy John Demaree Individual 10. Dec 18 10. Dec 18 1,000 €29.16 €29,163
31. Aug 18 Sell Jay Strum Individual 29. Aug 18 30. Aug 18 -10,000 €52.37 €-511,700
01. Jun 18 Sell Hatteras Venture Partners Company 30. May 18 30. May 18 -800,000 €41.26 €-33,008,640
24. May 18 Sell Hatteras Venture Partners Company 21. May 18 23. May 18 -37,500 €44.55 €-1,637,801
X
Management checks
We assess G1 Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. G1 Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

G1H News

Simply Wall St News

G1H Company Info

Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Details
Name: G1 Therapeutics, Inc.
G1H
Exchange: DB
Founded: 2008
$612,592,452
37,408,234
Website: http://www.g1therapeutics.com
Address: G1 Therapeutics, Inc.
79 T.W. Alexander Drive,
Suite 100,
Research Triangle Park,
North Carolina, 27709,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS GTHX Common Stock Nasdaq Global Select US USD 17. May 2017
DB G1H Common Stock Deutsche Boerse AG DE EUR 17. May 2017
Number of employees
Current staff
Staff numbers
84
G1 Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:01
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.